Document
IPR2019-00451, No. 12 Notice - Patent Owner Neurelis Incs Mandatory Change of Information Notices (P.T.A.B. Sep. 5, 2019)
Case IPR2019-00451 Patent No. 9,763,876 Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in a representative capacity for Patent Owner Neurelis, Inc. (Patent Owner), hereby submits the following mandatory change-of-information notices in connection with the petition for inter partes review identified in the caption.
Date: 5 September 2019
Respectfully submitted, /Richard Torczon/ Richard Torczon Reg. No. 34,448 Case IPR2019-00451 Patent No. 9,763,876
Cite Document
IPR2019-00451, No. 12 Notice - Patent Owner Neurelis Incs Mandatory Change of Information Notices (P.T.A.B. Sep. 5, 2019)
+ More Snippets
Document
IPR2019-00451, No. 10 Rehearing Request in re Petition Institution Decision Denied - Neurelis, Inc Request for Rehearing (P.T.A.B. Aug. 27, 2019)
The Federal Circuit has explained that “the description must ‘clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed.’” Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en banc), quoting Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1562-63 (Fed. Cir. 1991).
By sua sponte adding an extra-legal requirement for priority, the decision misapprehends the proper scope of the test and legally errs, significantly prejudicing Neurelis.
1348, 1356-57, 1360 (2018).2 Indeed, the rule itself does not 2 In Atmel Corp. v. Information Storage Devices, Inc., the court in dicta considered whether incorporation might be inappropriate for the corresponding structure of a means-plus-function claim, but ultimately held that the specification had sufficient
As noted previously, a Rule 57(h) requirement begins with the Office setting a time for response bounded by close of prosecution or abandonment, neither of which apply to a provisional application.
The formal objection raised sua sponte in the decision misapprehends a patentee’s legal obligations and the scope of the invoked rule, and overlooks contrary case law, Office guidance, and due-process requirements.
Cite Document
IPR2019-00451, No. 10 Rehearing Request in re Petition Institution Decision Denied - Neurelis, Inc Request for Rehearing (P.T.A.B. Aug. 27, 2019)
+ More Snippets
Document
IPR2019-00451, No. 11 Objection - Neurelis, Inc Objections (P.T.A.B. Aug. 27, 2019)
Cite Document
IPR2019-00451, No. 11 Objection - Neurelis, Inc Objections (P.T.A.B. Aug. 27, 2019)
+ More Snippets
Document
IPR2019-00451, No. 6 Notice - Patent Owners Mandatory Notices (P.T.A.B. May. 21, 2019)
Cite Document
IPR2019-00451, No. 6 Notice - Patent Owners Mandatory Notices (P.T.A.B. May. 21, 2019)
+ More Snippets
Document
IPR2019-00451, No. 7 Preliminary Response - Patent Owner Preliminary Response (P.T.A.B. May. 21, 2019)
Cite Document
IPR2019-00451, No. 7 Preliminary Response - Patent Owner Preliminary Response (P.T.A.B. May. 21, 2019)
+ More Snippets
Document
IPR2019-00451, No. 4 Mandatory Notice - Patent Owners Mandatory Notices (P.T.A.B. Feb. 19, 2019)
Cite Document
IPR2019-00451, No. 4 Mandatory Notice - Patent Owners Mandatory Notices (P.T.A.B. Feb. 19, 2019)
+ More Snippets
Document
IPR2019-00451, No. 1 Power of Attorney - Power of Attorney (P.T.A.B. Jan. 29, 2019)
Cite Document
IPR2019-00451, No. 1 Power of Attorney - Power of Attorney (P.T.A.B. Jan. 29, 2019)
+ More Snippets
Document
IPR2019-00451, No. 2026-158 Exhibit - Affidavit of Ronald Figueroa (P.T.A.B. Apr. 28, 2020)
Cite Document
IPR2019-00451, No. 2026-158 Exhibit - Affidavit of Ronald Figueroa (P.T.A.B. Apr. 28, 2020)
+ More Snippets
Document
IPR2019-00451, No. 2030-154 Exhibit - J Wyse, US Patent No 9,192,570 issued November 24, 2015 (P.T.A.B. Mar. 10, 2020)
Cite Document
IPR2019-00451, No. 2030-154 Exhibit - J Wyse, US Patent No 9,192,570 issued November 24, 2015 (P.T.A.B. Mar. 10, 2020)
+ More Snippets
Document
IPR2019-00451, No. 1070-96 Exhibit - Gizurarson, Patent Application Publication No US 20080275030, Nov 6, 2008 (P.T.A.B. Jan. 28, 2020)
Cite Document
IPR2019-00451, No. 1070-96 Exhibit - Gizurarson, Patent Application Publication No US 20080275030, Nov 6, 2008 (P.T.A.B. Jan. 28, 2020)
+ More Snippets
Document
IPR2019-00451, No. 1119-123 Exhibit - Davis GA, Rudy AC, Archer SA, Wermeling DP, McNamara PJ Effect of fluticasone propionate nasal spray on bioavailability of hydromorphone hydrochlo...
Cite Document
IPR2019-00451, No. 1119-123 Exhibit - Davis GA, Rudy AC, Archer SA, Wermeling DP, McNamara PJ Effect of fluticasone propionate nasal spray on bioavailability of hydromorphone hydrochloride in patient
+ More Snippets
Document
IPR2019-00451, No. 1082-104 Exhibit - Chien, YW, et al, Nasal Systemic Drug Delivery, Chapter 1, Anatomy and Physiology of the Nose, Drugs and the Pharmaceutical Sciences, Vol 39, Marcel ...
Cite Document
IPR2019-00451, No. 1082-104 Exhibit - Chien, YW, et al, Nasal Systemic Drug Delivery, Chapter 1, Anatomy and Physiology of the Nose, Drugs and the Pharmaceutical Sciences, Vol 39, Marcel Decker, 1989
+ More Snippets
Document
IPR2019-00451, No. 1129-130 Exhibit - Burstein AH, Modica R, Hatton M, et al Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration J Clin Pharmacol 1997 37 7...
Cite Document
IPR2019-00451, No. 1129-130 Exhibit - Burstein AH, Modica R, Hatton M, et al Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration J Clin Pharmacol 1997 37 711 718 (P.T.A.
+ More Snippets
Document
IPR2019-00451, No. 1135-134 Exhibit - Greenblatt D, Gan L, Harmatz, et al Pharmacokinetics and pharmacodynamics of single dose triazolam EEG compared with digital symbol substitution te...
Cite Document
IPR2019-00451, No. 1135-134 Exhibit - Greenblatt D, Gan L, Harmatz, et al Pharmacokinetics and pharmacodynamics of single dose triazolam EEG compared with digital symbol substitution test Br J Clin
+ More Snippets
Document
IPR2019-00451, No. 1144-143 Exhibit - Ahmad S, Ellis J, Kamwendo H, et al Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children...
Cite Document
IPR2019-00451, No. 1144-143 Exhibit - Ahmad S, Ellis J, Kamwendo H, et al Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children an open l
+ More Snippets